SL-82. p38α Inhibitors

ASINEX
Signature Libraries

P38 mitogen-activated protein kinases (MAPK) are widely expressed in endothelial, immune, and inflammatory cells and play a central role in the regulation of proinflammatory cytokine production. Among p38 MAPK family isoforms, isoform alpha is most studied and represents an attractive target for the development of anti-inflammatory therapeutics [1]. A number of natural product and synthetic inhibitors of p38 kinase family has been reported showing a promising anti-inflammatory activity in several models [2]. However, low specificity, low efficacy, and high toxicity of known candidates, creates an unmet need for novel agents.

Using a proprietary library design platform ASINEX has created molecules that *in vitro* target p38a in a range of therapeutically relevant concentrations



LMK 22313306



SYN 22329787



ASN 10398328



SC79659



AMG 548



VX-745

Signature Library 82

Formats	Supplementary Information
80 compounds per plate 0.1 mg; 1 mg; 2 mg dry film/powder 0.1 µmol; 1 µmol DMSO solutions	SL#80_p38_inhibitors.sdf

References:

1. . *J Med Chem. 2010 Mar 25;53(6):2345-53*. doi: 10.1021/jm9012906
2. *Mediators Inflamm. 2014;2014:352371*. doi: 10.1155/2014/352371.

Contact us:

USA:	+1 336 721 1617	asinex@asinex.com
Japan:	+81-80-3401-9097	sota@asinex.com
Europe/Global:		lsadovenko@asinex.com

ASINEX
Signature Libraries

asinex.com